Provided by Tiger Fintech (Singapore) Pte. Ltd.

Protagonist Therapeutics

44.49
-0.3600-0.80%
Post-market: 44.490.00000.00%17:35 EDT
Volume:634.14K
Turnover:28.12M
Market Cap:2.73B
PE:10.52
High:44.84
Open:44.36
Low:43.62
Close:44.85
Loading ...

Protagonist Therapeutics Price Target Maintained With a $50.00/Share by HC Wainwright & Co.

Dow Jones
·
11 Nov 2024

Bullish Outlook on Protagonist Therapeutics Amid Promising JNJ-2113 Phase 3 Trial Potential

TIPRANKS
·
11 Nov 2024

Protagonist Therapeutics (PTGX) Gets a Buy from J.P. Morgan

TIPRANKS
·
09 Nov 2024

Protagonist Therapeutics Inc reports results for the quarter ended in September 30 - Earnings Summary

Reuters
·
08 Nov 2024

Positive Outlook and Buy Rating for Protagonist Therapeutics Based on Promising Phase III Results and Strategic Positioning

TIPRANKS
·
08 Nov 2024

Protagonist Therapeutics (PTGX) Reports Q3 Loss, Tops Revenue Estimates

Zacks
·
08 Nov 2024

Protagonist Therapeutics Q3 EPS $(0.54) Beats $(0.63) Estimate, Sales $4.67M Beat $2.07M Estimate

Benzinga
·
08 Nov 2024

Protagonist Therapeutics: Q3 Earnings Snapshot

Associated Press Finance
·
08 Nov 2024

Protagonist Therapeutics Q3 Operating Expenses USD 46.128 Million

THOMSON REUTERS
·
08 Nov 2024

Protagonist Therapeutics Announces Poster Presentation on Final REVIVE Phase 2 Study Data with Rusfertide at the 66th Annual ASH Meeting

ACCESSWIRE
·
06 Nov 2024

Wedbush Initiates Protagonist Therapeutics at Outperform With $58 Price Target

MT Newswires Live
·
05 Nov 2024

Protagonist Therapeutics Initiated at Outperform by Wedbush

Dow Jones
·
05 Nov 2024

Protagonist Therapeutics Inc : Wedbush Initiates Coverage With Outperform Rating; Target Price $58

THOMSON REUTERS
·
05 Nov 2024

Wedbush starts Protagonist Therapeutics with an Outperform, $58 target

TIPRANKS
·
05 Nov 2024

Protagonist Therapeutics Inc expected to post a loss of 62 cents a share - Earnings Preview

Reuters
·
02 Nov 2024

Protagonist Therapeutics Inc expected to post a loss of 60 cents a share - Earnings Preview

Reuters
·
31 Oct 2024

Protagenic Therapeutics Announces Pricing of Private Placement for Aggregate Gross Proceeds of $1.275 Million

ACCESSWIRE
·
29 Oct 2024